Published in Viruses on May 21, 2015
Oncogenic human papillomaviruses. Philos Trans R Soc Lond B Biol Sci (2017) 0.75
Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis. Front Immunol (2016) 0.75
Host cell restriction factors that limit transcription and replication of human papillomavirus. Virus Res (2016) 0.75
Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'. Br J Cancer (2016) 0.75
The Mouse Papillomavirus Infection Model. Viruses (2017) 0.75
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Classification of papillomaviruses. Virology (2004) 14.16
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Crosstalk in NF-κB signaling pathways. Nat Immunol (2011) 6.05
Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev (1998) 4.06
Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol (2002) 3.91
Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) (2006) 3.74
Regulation of type I interferon responses. Nat Rev Immunol (2014) 3.60
The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol (2013) 3.59
Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 3.52
The papillomavirus life cycle. J Clin Virol (2005) 3.41
Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol (1991) 2.79
The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J (1999) 2.44
Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol (2000) 2.44
Type I interferons in infectious disease. Nat Rev Immunol (2015) 2.37
CD40 is functionally expressed on human thymic epithelial cells. J Immunol (1992) 2.29
The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol (1999) 1.94
European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol (2010) 1.86
HPV-associated skin disease. J Pathol (2006) 1.74
Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med (2008) 1.72
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J (2008) 1.66
Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis (2010) 1.56
Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem (2000) 1.52
The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol (1995) 1.48
The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology (1999) 1.46
The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene (1999) 1.44
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol (2003) 1.43
The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem (2002) 1.39
Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J (2009) 1.36
Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene (2003) 1.36
Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis (2009) 1.35
The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem (2004) 1.34
Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol (2002) 1.32
Heritability of cervical tumours. Int J Cancer (2000) 1.32
Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol (2008) 1.30
cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J Biol Chem (2000) 1.28
Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell (2008) 1.27
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26
E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer (2005) 1.24
Diseases associated with human papillomavirus infection. Virology (2013) 1.18
E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer (2006) 1.18
High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol (2011) 1.16
Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog (2013) 1.15
Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis (2006) 1.11
The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem (2002) 1.11
Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer (2007) 1.11
High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins. Virology (2005) 1.10
Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res (2009) 1.09
Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol (2011) 1.08
p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. J Immunol (2011) 1.08
Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Cell Mol Life Sci (2006) 1.08
Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kappaB activation. Arterioscler Thromb Vasc Biol (2007) 1.07
Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res (2009) 1.07
SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep (2012) 1.03
Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod (2006) 1.03
Differential production of cytokines and activation of NF-kappaB in HPV-transformed keratinocytes. Virology (2002) 1.02
Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J Virol (2002) 1.02
The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology (2003) 1.02
The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med (2013) 1.01
Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog (2013) 1.00
HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene (2005) 1.00
Bap31 is a novel target of the human papillomavirus E5 protein. J Virol (2008) 1.00
E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-κ transcription in keratinocytes. PLoS One (2014) 0.99
Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J Virol (2011) 0.99
Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene (2000) 0.98
The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene (2000) 0.98
Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. Virology (2006) 0.97
Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology (2012) 0.97
HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology (2010) 0.96
The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathog (2013) 0.94
CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol (2010) 0.92
Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer (2014) 0.90
Adeno-associated virus type 2 rep protein inhibits human papillomavirus type 16 E2 recruitment of the transcriptional coactivator p300. J Virol (2000) 0.90
Immunotherapy for persistent viral infections and associated disease. Trends Immunol (2011) 0.90
Increased p50/p50 NF-kappaB activation in human papillomavirus type 6- or type 11-induced laryngeal papilloma tissue. J Virol (2002) 0.89
Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int J Mol Med (2000) 0.89
The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology (2000) 0.88
Interaction of Bap31 and MHC class I molecules and their traffic out of the endoplasmic reticulum. J Immunol (2009) 0.88
The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol J (2007) 0.88
HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. Biochem Biophys Res Commun (2006) 0.87
Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J Gen Virol (2013) 0.86
Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. Diagn Cytopathol (2006) 0.85
HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res (2013) 0.85
CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV. J Invest Dermatol (2014) 0.83
NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity. J Virol (2010) 0.83
HPV16 E2-mediated potentiation of NF-κB activation induced by TNF-α involves parallel activation of STAT3 with a reduction in E2-induced apoptosis. Mol Cell Biochem (2014) 0.81
Genetic variation in the TLR and NF-κB pathways and cervical and vulvar cancer risk: a population-based case-control study. Int J Cancer (2013) 0.81
EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production. Am J Physiol Lung Cell Mol Physiol (2014) 0.81
Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression. J Biol Chem (2011) 0.80
The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation. Nat Commun (2015) 0.80
Repression of MHC class I transcription by HPV16E7 through interaction with a putative RXRbeta motif and NF-kappaB cytoplasmic sequestration. Biochem Biophys Res Commun (2009) 0.80
E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis. J Int Med Res (2014) 0.80
All 4 di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I downregulation activity and E5 endomembrane localization. Int J Cancer (2010) 0.79
Keratinocyte sensitization to tumour necrosis factor-induced nuclear factor kappa B activation by the E2 regulatory protein of human papillomaviruses. J Gen Virol (2011) 0.78
Keratinocytes efficiently process endogenous antigens for cytotoxic T-cell mediated lysis. Exp Dermatol (2009) 0.78